Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain
finance.yahoo.com/news/...tml?soc_src=social-sh&soc_trk=tw
finance.yahoo.com/news/...tml?soc_src=social-sh&soc_trk=tw